The activation of PPAR-α also improves anti-tumor immunity in PD-1 blockade cancer immunotherapy by reprogramming CD8+ T-cell metabolism from glycolysis to increased mitochondrial OXPHOS and FAO, supporting the extra energy demands of effector CTLs, thus lengthening the survival and potentiating activity (65, 66). Here, PPARA is linked to cancer.